VEGFR2/CD309 Antikörper (N-Term)
Kurzübersicht für VEGFR2/CD309 Antikörper (N-Term) (ABIN926995)
Target
Alle VEGFR2/CD309 (VEGFR2) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- N-Term
-
Kreuzreaktivität
- Hund
-
Aufreinigung
- Purified
-
Immunogen
- KDR antibody was raised in rabbit using the N terminal of KDR as the immunogen
-
-
anti-VEGF Receptor 2 (VEGFR2) (AA 20-200) antibody
VEGFR2 Reaktivität: Human WB, IHC Wirt: Kaninchen Polyclonal unconjugated
anti-VEGF Receptor 2 (VEGFR2) (AA 1326-1356), (C-Term) antibodyVEGFR2 Reaktivität: Human WB, FACS, IF, IHC (p) Wirt: Kaninchen Polyclonal RB01536 unconjugated
anti-VEGF Receptor 2 (VEGFR2) (pTyr951) antibodyVEGFR2 Reaktivität: Human, Maus, Ratte WB, IHC, ELISA, IF, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-VEGF Receptor 2 (VEGFR2) (AA 20-242) antibodyVEGFR2 Reaktivität: Human WB, IHC, FACS, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-VEGF Receptor 2 (VEGFR2) (AA 1326-1356) antibodyVEGFR2 Reaktivität: Human WB, IHC, ELISA, FACS, IF Wirt: Kaninchen Polyclonal unconjugated
anti-VEGF Receptor 2 (VEGFR2) (AA 101-200) antibodyVEGFR2 Reaktivität: Human, Maus, Ratte, Kaninchen ELISA, FACS, IHC (p), IF (p), IHC (fro) Wirt: Kaninchen Polyclonal unconjugated
anti-VEGF Receptor 2 (VEGFR2) (AA 20-764) antibodyVEGFR2 Reaktivität: Human ELISA, FACS, ICC Wirt: Maus Monoclonal 4B4 unconjugated
anti-VEGF Receptor 2 (VEGFR2) (AA 1225-1356) antibodyVEGFR2 Reaktivität: Human ELISA, FACS Wirt: Maus Monoclonal 1A9A3 unconjugated
anti-VEGF Receptor 2 (VEGFR2) (pTyr1214) antibodyVEGFR2 Reaktivität: Human, Maus, Ratte WB, IHC, ELISA, IF, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-VEGF Receptor 2 (VEGFR2) (AA 454-469), (Middle Region) antibodyVEGFR2 Reaktivität: Human WB, IHC, ICC Wirt: Kaninchen Polyclonal unconjugated
-
-
Applikationshinweise
-
WB: 0.2-1 µg/mL
Optimal conditions should be determined by the investigator. -
Kommentare
-
KDR Blocking Peptide, , is also available for use as a blocking control in assays to test for specificity of this KDR antibody
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Konzentration
- Lot specific
-
Buffer
- Lyophilized powder. Add 50 µL of distilled water. Final antibody concentration is 1 mg/mL in PBS buffer.
-
Handhabung
- Avoid repeated freeze/thaw cycles.
-
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store at 4 °C, following reconstitution, aliquot and store at -20 °C.
-
-
- VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))
-
Andere Bezeichnung
- KDR
-
Hintergrund
- KDR is the receptor for VEGF or VEGFC. It has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. Synonyms: Polyclonal KDR antibody, Anti-KDR antibody, kinase insert domain receptor, a type III receptor tyrosine kinase antibody, CD309 antibody, FLK1 antibody, VEGFR antibody, VEGFR2 antibody.
-
Pathways
- RTK Signalweg, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling
Target
-
